



---

**Notice of Meeting to Solicit Public Comments and Intent to Act  
Upon Amendments to the Medicaid Services Manual (MSM)**

**Public Hearing November 24, 2020  
Summary**

Date and Time of Meeting: November 24 at 9:02 AM

Name of Organization: State of Nevada, Department of Health and Human Services (DHHS), Division of Health Care Financing and Policy (DHCFP)

Place of Meeting: WebEx

**Teleconference and/or WebEx Attendees**

**(Note: This List May Not Include All Participants, Just Those Who Identified Themselves)**

Gabriel Lither, Senior Deputy Attorney General (SDAG)  
DuAne Young, Deputy Administrator, DHCFP  
Sydney Banks, JK Belz & Associates  
Jessica Kemmerer, DHCFP  
Antonio Gudino, DHCFP  
Annette Piccirilli, Optum  
Carl Jeffery, Optum

Valerie Balen, JK Belz & Associates  
Jovanna Leid, DXC  
Jimmy Lau, Ferrari Public Affairs  
Ellen Flowers, DHCFP  
Lori Follett, DHCFP  
Paula Pence, DHCFP

**Introduction:**

Jessica Kemmerer, HIPAA Privacy Officer, DHCFP opened the Public Hearing introducing herself, DuAne Young, Deputy Administrator, DHCFP and Gabriel Lither, SDAG.

Jessica Kemmerer – The notice for this public hearing was published on October 22, 2020 in accordance with the Nevada Revised Statute (NRS) 422.2369.

**1. Public Comment**

No Comments.

**2. Discussion and adoption of changes to MSM Chapter 1200 – Prescribed Drugs**

Antonio Gudino, Social Services Program Specialist for the Pharmacy Unit, presented on the proposed revisions to MSM Chapter 1200 – Prescribed Drugs, which are based on recommendations approved at the July 23, 2020 Drug Use Review Board Meeting.

The proposed changes include revisions to the existing prior authorization (PA) criteria for psychotropic medications for children and adolescents, addition of new PA criteria for Somavert®(pegvisomant) and

addition of new PA criteria for Valtoco® (diazepam). Furthermore, the DHCFP is proposing revisions to the existing PA criteria within the Antimigraine Medication agents, to correct duplicative criteria.

The following providers who prescribe, dispense or administer these drugs may be affected by this change, including but not limited to the listed Provider Types (PTs) on the agenda.

There is no financial impact on local government known.

The effective date for these changes is November 30, 2020.

The location and details of the changes begin with Section D, titled “Growth Hormones,” where new prior authorization (PA) criteria for Somavert® (pegvisomant) has been added.

The next proposed change can be found within Section N, titled “Psychotropic Medications for Children and Adolescents.” Due to further research on the proposed policy, only grammatical changes to this section will be adopted. Any proposed policy changes will be presented at a future date.

The next proposed change is found in Section S, titled “Antimigraine Medication.” The policy language for Episodic Migraines and Chronic Migraines was removed to correct the clinical criteria as this was duplicative in error.

The next proposed change is found in Section BB, titled “Substance Abuse Agents,” where the word Buprenorphine was added for clarification, as the clinical criteria applies to both the buprenorphine agent and the combination buprenorphine/naloxone agent.

Lastly, on Section BBB, titled “Anticonvulsants,” new PA criteria for Valtoco® (diazepam) was added.

At the conclusion of Antonio Gudino’s presentation, Jessica Kemmerer asked DuAne Young and Gabriel Lither if they had any questions or comments, and they had none. DuAne Young did clarify the correction made by Antonio Gudino.

Jessica Kemmerer asked if there were any other questions or comments, and there were none.

Jessica Kemmerer – Recommended the Deputy Administrator approve the proposed changes to MSM Chapter 1200.

DuAne Young – Approved as submitted with the change Antonio Gudino mentioned in Section N.

3. Jessica Kemmerer – Closed the Public Hearing for the MSM Chapter 1200 – Prescribed Drugs

4. **Adjournment**

There were no further comments and Jessica Kemmerer adjourned the public hearing at 9:06 AM.

***\*An Audio (CD) version of this meeting is available through the DHCFP Compliance office. For more detailed information on any of the handouts, submittals, testimony and or comments, please contact Jenifer Graham at [jenifer.graham@dncfp.nv.gov](mailto:jenifer.graham@dncfp.nv.gov) with any questions.***